Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer

Zhu Wang1,2,*, Dinglan Wu1,3,*, Chi-Fai Ng4, Jeremy Yuen-Chun Teoh4, Shan Yu1, Yuliang Wang1 and Franky L Chan1

1School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China
2Department of Urology, People’s Hospital of Longhua, Shenzhen, China
3The Clinical Innovation & Research Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China
4Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Correspondence should be addressed to Y Wang or F L Chan: yuliang.wang816@gmail.com or franky-chan@cuhk.edu.hk

*Z Wang and D Wu contributed equally to this work

Abstract

Nuclear receptors (NRs), which belong to a superfamily of transcription factors and consist of a total of 48 members in humans, govern the expression of genes involved in a broad range of developmental, reproductive, metabolic and immunological programs. Given the significant importance of androgen receptor and a few known NRs in the progression of prostate cancer, we surveyed the expression profiles of the entire NR superfamily in three-dimensional cultured prostatospheroids derived from different prostate cancer cell lines and a tumor xenograft model of castration-resistant prostate cancer VCaP-CRPC by quantitative real-time RT-PCR. Our results revealed that prostatospheroids and castration-relapse VCaP-CRPC xenografts, both contained enriched populations of prostate cancer stem/progenitor-like cells (PCSCs), displayed distinct expression patterns of NRs. Intriguingly, most of these differentially expressed NRs were orphan NRs and showed upregulation. Pairwise analysis identified five orphan NRs (including RORβ, TLX, COUP-TFI, NURR1 and LRH-1) that showed common upregulation in both mRNA and protein levels in the prostatospheroids and castration-relapse VCaP-CRPC xenografts, and overexpression of these orphan NRs could increase cancer stem cell marker expressions and enhance spheroid formation capacity in prostate cancer cells, suggesting that these orphan NRs might perform positive roles in the growth regulation of PCSCs and castration-resistant prostate cancer. Together, our NR expression dataset not only revealed the distinct physiologic status and regulatory roles governed by the networks of specific NRs but also some of these identified orphan NRs could be the potential therapeutic targets for PCSCs or castration-resistant prostate cancer.

Key Words

- nuclear receptors
- orphan nuclear receptors
- prostate cancer
- castration resistance
- prostate cancer stem-like cells

Introduction

It is well established that the normal and neoplastic growth of prostate gland is significantly driven by androgen via its cognate androgen receptor (AR). Based on this androgen-dependent characteristic, it forms the biological basis of hormone therapy for prostate cancer (androgen deprivation by castration or AR-axis targeted therapy by antiandrogens) by targeting mainly the AR-axis signaling, as proposed originally by Huggins
and Hodges in the 1940s (Huggins & Hodges 1941) and remains the frontline treatment option for the advanced prostate cancer. It is also recognized that dysregulation of AR signaling and androgen metabolism, including AR hypersensitivity to castration levels of androgens due to AR overexpression or antagonist-to-agonist switch due to AR mutation and intra-tumoral androgen biosynthesis, are critically involved in its advanced progression to androgen-insensitive and metastatic stages (castration-resistant or hormone-refractory prostate cancer CRPC) and are also believed to be the main causes for the failure of hormone therapy (Yuan et al. 2014, Karantanos et al. 2015). Targeting these compensatory mechanisms that allow reactivation of AR-axis signaling in therapy-resistant patients, novel antiandrogen (enzalutamide) and androgen biosynthesis inhibitor (CYP17A1-targeting abiraterone acetate) have been recently developed and applied as novel AR-axis-targeted therapies. The clinical outcomes by these novel hormone therapies show significant improvement on overall survival in patients with metastatic CRPC (Ryan et al. 2015). Despite these advances, adopted secondary resistance to enzalutamide or abiraterone soon develops in patients and such resistance is shown to involve the expression of AR splice variants, particularly the constitutively active ligand-binding domain (LBD) deleted AR-V7 (Antonarakis et al. 2014). Furthermore, detection of AR-V7 variant or mutated AR in circulating tumor cells or cell-free serum is shown useful to predict the treatment response or prognosis of CRPC patients (Steinestel et al. 2015, Lallous et al. 2016). In some CRPC patients, the disease will evolve to a highly aggressive and treatment-resistant CRPC, characterized by acquired neuroendocrine cell-specific phenotype and loss of AR, of which treatment option is limited and results in high mortality. Accumulating pieces of evidence suggest that prostate cancer stem/progenitor-like cells (PCSCs, also called prostate cancer stem cells, tumor initiating or progenitor cells) may contribute to the advanced growth of metastatic CRPC. The mechanisms and signaling pathways involved in the growth regulation of PCSCs are still largely unclear. Therefore, it is of utmost importance to identify novel therapeutic targets for the advanced therapy-resistant prostate cancer.

Nuclear receptors (NRs) belong to a superfamily of DNA-binding transcription factors and consist of a total of 48 members in humans. They comprised the commonly conserved modular DNA-binding domain and C-terminal LBD. Studies in past decades indicate that they play important regulatory roles virtually in all biological processes and cellular functions, and are also involved in many diseases. Thus, many NR members are promising drug targets or being used as established therapeutic targets for different diseases, including diabetes and cancers. Based on the presence or absence of physiological ligands, NRs are generally grouped into hormone receptors, adopted orphan receptors and genuine orphan receptors (Chawla et al. 2001). Indeed, besides AR, many members of NR superfamily are also expressed in human prostate gland and prostate cancer cells (Cheung et al. 2005). Some hormone NRs are shown to play multiple roles in the prostate cancer progression and their pharmacological manipulation can therapeutically intervene the growth of prostate cancer. For example, glucocorticoid receptor (GR) can act to antagonize AR signaling in prostate cancer and glucocorticoid treatment is either used singly or in combination with chemotherapy and abiraterone acetate for metastatic CRPC (Sahu et al. 2013, Kach et al. 2015). Vitamin D receptor (VDR) can crosstalk with AR and its activation can modulate androgen metabolism and suppress prostate cancer cell proliferation via different mechanisms (Ahn et al. 2016). Use of calcitriol (active vitamin D3 metabolite) in combination with chemotherapy can exert certain beneficial effects on some CRPC patients, though not clinically and fully established yet (Ben-Eliriki et al. 2016). Recent advances show that some orphan NRs, including RORγ (NR1F3) (Wang et al. 2016), TRs (NR2C1, NR2C2) (Mu & Chang 2003, Lin et al. 2015), TLX (NR2E1) (Wu et al. 2015), COUP-TFI (NR2F2) (Qin et al. 2013), ERRs (NR3B1/2/3) (Yu et al. 2007, 2008, Zou et al. 2014), NGFI-B (NR4A1) (Yu et al. 2014), DAX1 (NR0B1) (Agoulnik et al. 2003) and SHP (NR0B2) (Yuan et al. 2001), can either promote or suppress prostate cancer growth via their diverse AR-associated or -independent signaling pathways. Intriguingly, it is shown that some orphan NRs may have potential therapeutic values for prostate cancer as modulation of their activities by ligands or small molecules could suppress the growth of prostate cancer cells.

The quantitative RT-PCR has been used to characterize and quantify the expression profiles of the entire NR superfamily in certain human organs (Nishimura et al. 2004), some specific cell types and their differentiation status (including immune cells (Schote et al. 2007), adipocytes and adipogenesis (Lahnalampi et al. 2010), fat-accumulated hepatocytes and hepatoma cells
Establishment of castration-resistant prostate cancer
tumor xenografts

VCaP cells (2 × 10^6 cells/100 µL mixed 1:1 in Matrigel) were
injected subcutaneously into the flanks of 6–8-week-old
intact male SCID mice and allowed to grow for 14 weeks
totally. Host-mice-bearing tumor xenografts were then
orchietomized when tumor sizes reached about 0.8 cm^3.
The relapsed tumor xenografts were allowed to grow to
sizes of about 1.2 cm^3. In some host-mice-bearing relapse
tumors, animals were further treated with abiraterone
(0.5 mmol/kg/day) for 3 weeks. Needle biopsies of tumor
xenografts were acquired on same days when castration
was performed (pre-castration), 4-day post-castration
and 8-week post-castration (castration-relapse) for mRNA
and flow cytometry analyses.

RNA extraction and qRT-PCR analysis

Total RNA was extracted from cultured cells and tumor
xenografts using TRIzol reagent, and treated with DNaseI.
First-strand cDNA was synthesized with 1 µg RNA using
PrimeScript RTase and a mixture of oligo-dT and random
hexamers (PrimeScript RT Master Mix, Takara) at 37°C for
15 min, followed by heat inactivation of RTase at 85°C for
5 s. qRT-PCR was performed using an SYBR green
fluorescence-based method. Briefly, PCR reactions were assembled
by mixing 25 ng of cDNA, 150 nM of primer pairs and SYBR
green master mix (SYBR Premix Ex Taq, ROX Plus, Takara)
and was performed in a real-time PCR system (StepOne,
Applied Biosystems) at 95°C for 20 s, followed by 40 three-
step cycles of 95°C for 15 s, 60°C for 20 s and 72°C for 30 s. We
evaluated the expressions of totally 10 housekeeping
genes in prostatic cells cultured at different conditions using
validated PCR primer sets (RealTimePrimers.com) in order
to identify the appropriate housekeeping gene for qRT-
PCR analysis. Results showed that all tested housekeeping
genes, including β-actin, exhibited same expressions levels
in both adherent cultured cells and prostatospheroids
(Supplementary Fig. 1, see section on supplementary data
given at the end of this article). Relative mRNA levels were
determined using the comparative Δ−CT method and
normalized against β-actin. The specificity of the primers
was validated by the melting-curve detection. mRNA levels
with cycle threshold (CT) values ≥34 were considered as
below detection (Bookout et al. 2006, Jeong et al. 2012).
Primer sequences for all NRs and cancer stem-like cell
biomarkers, and the mean PCR-amplification CT values of
all NRs expressed in 2D-monolayer prostate cancer cells
are listed in Supplementary Tables 1, 2, 3, 4, 5 and 6.
Plasmid construction and lentiviral transduction

Full-length cDNAs of human RORβ, TLX, COUP-TFI, NURR1 and LRH-1 were amplified by PCR using plasmid clones obtained from DNASU Plasmid Repository (Arizona State University), FLAG-tagged and subcloned into lentiviral plasmid pWPI for overexpression study. For production of lentiviruses, constructed or empty pWPI plasmids were transfected into 293FT packaging cells. To generate stable infectants, LNCaP and DU145 cells were infected with orphan NR-expressing viruses following procedures as described previously (Wu et al. 2015). The generated infectants were validated by RT-PCR and immunoblot analyses before use.

Immunoblotting

Whole cell proteins were extracted from subconfluent cultured cells, isolated spheres and re-adherent cells from spheres using a cold lysis buffer (20mM PIPES, 0.1% SDS, 1mM EDTA, 1mM EGTA, 10mM monothioglycerol, 1mM PMSF, 5mM leupeptin, 0.25M sucrose). After SDS-PAGE separation and transblotting onto PVDF membranes, resolved proteins were probed with optimally diluted primary and secondary antibodies followed by a chemiluminescent detection method (ECL Western Blotting Detection System, Amersham). Primary antibodies used are as follows: RORβ (EPR15552, Abcam), TLX (Wu et al. 2015), COUP-TFI (H7147, Abcam), NURR1 (N1404, Abcam) and LRH-1 (H2325, Abcam).

Immunofluorescence

Cryostat sections of OCT-embedded and frozen tumor xenografts were fixed with 4% paraformaldehyde, membrane-permeabilized with PBS-buffered 0.1% Triton X-100 and blocked with 5% normal goat serum, followed by staining with primary FITC-conjugated CD44 antibody and APC-conjugated CD133 antibody (#130-095-195, #130-097-049, Miltenyi Biotec GmbH) for 10min at 4°C to sort out the CD44+/CD133+ cell populations using a flow cytometer (Beckman Coulter FC500 MCL/MPL Counter). At least three independent experiments were performed on each sample.

ONCOMINE oncogenic analysis

The differential mRNA expression levels of NRs identified in our models were validated in prostate cancer clinical samples and normal prostate gland tissues using TCGA datasets in ONCOMINE database (http://www.oncomine.org). The parameters used for the analysis include the official gene names of the NRs as primary filter, and the expression levels in cancer versus normal tissue as analysis type. The threshold used to obtain the most significant probes of the queried gene for each microarray data included a two-fold difference in expression between cancers and normal tissues with a P value <1 × 10^-4.

Data analysis

The relative fold changes (RFC) of mRNA levels were determined by the comparative threshold cycle method (2^-∆∆Ct) and normalized to β-actin. NR mRNA levels with cycle times ≥34 were considered as beyond detection. NR mRNA levels with RFC ≥2.0 were interpreted as upregulation and with RFC ≤0.5 as downregulation as compared to their reference samples, whereas with RFC within 0.5–2.0 were considered as not significantly and statistically different from that of reference sample. Data analysis and normalization to control gene expression were performed with the SDS2.2 software (Applied Biosystems). Data were expressed as mean±s.d. Wilcoxon non-parametric test was utilized for statistical analysis and a P value <0.05 was considered statistically significant.

Results

PCSC-enriched prostatospheroids exhibit increased expression of stem-like cell markers

It is well characterized that cellular aggregates or spheroids formed under the non-adherent 3D-culture condition from single-cell suspensions derived from various primary
or tumor tissues are enriched in stem or progenitor cells (Pastrana et al. 2011), likely due to their anchorage-independent growth capacity. Based on this, single-cell-based and non-adherent sphere formation assays have been widely used to identify and isolate the putative prostatic stem-like cells or PCSCs derived from various in vitro and in vivo prostatic sources for self-renewal and differentiation analyses (Li et al. 2009, Lukacs et al. 2010). Here, we performed the sphere formation assay on three established prostate cancer cell lines differing in their AR expression status (AR-positive: LNCaP and VCaP; AR-negative: DU145) in order to enrich the PCSCs for entire NR member expression analysis. Results of qRT-PCR analysis showed that the isolated spheroids or prostatospheroids derived from different prostate cancer cell lines exhibited significantly increased expression levels of PCSC markers as compared to their parental cells grown under the conventional 2D adherent condition, indicating that these prostatospheroids were enriched in PCSCs (Fig. 1).

Prostatospheroids display distinct expression profiles of NRs

Increasing pieces of evidence indicate that certain members of NR superfamily play important roles in the regulation of stemness and differentiation of both embryonic stem cells and various types of adult tissue-specific stem cells (Jeong & Mangelsdorf 2009). In order to identify the members of NR superfamily, which would be involved in prostatospheroid formation or play roles in the growth of PCSCs, we determined the expression profiles of the total 48 NR members in prostatospheroids derived from three prostate cancer cell lines by the qRT-PCR method, which can assess the relative expression levels of NR transcripts and also their changes of levels in prostate cancer cells upon hormone manipulation. Results showed that a broad range of NRs, particularly the orphan NR members, were expressed in both adherent cultured prostate cancer cells and PCSC-enriched prostatospheroids. Analysis of
expression profiles of NR members in prostatospheroids further revealed that a total of 33 NRs were significantly upregulated in LNCaP-prostatospheroids, 27 NR members in VCaP-prostatospheroids and 36 NR members in DU145-prostatospheroids (Fig. 2A, B and C). Further analysis identified that among these NRs with increased expressions, 21 members exhibited common upregulation pattern in prostatospheroids derived from three prostate cancer cell lines. These included 3 endocrine NRs, 3 adopted NRs and 15 ligand-independent orphan NRs (listed in Fig. 2D).

**Figure 2**
Prostatospheroids display distinct expression profiles of NRs. (A, B and C) Histograms show the relative fold changes (RFC) of expressions of NRs in prostatospheroids derived from (A) LNCaP, (B) VCaP and (C) DU145 prostate cancer cell lines. NRs are grouped according to their ligand dependence as endocrine, adopted and orphan NRs. RFC of NR expressions were normalized to that in adherent 2D-cultured parental cells. The normalized NR expression levels are defined as upregulated if RFC values ≥2.0, downregulated if RFC values ≤0.5, no significant change if RFC values within 0.5–2.0, and undetected if Ct value >34. Results showed that many members of NRs showed significant upregulation in prostatospheroids. (D) Left: data analysis summarized that a total of 21 NR members exhibited common upregulation in prostatospheroids derived from three prostate cancer cell lines. Middle: pie chart shows the number of endocrine, adopted and orphan NRs with common upregulation in prostatospheroids. Right: table shows the trivial and gene names of upregulated NRs in prostatospheroids.
Results also identified that some NR members exhibited diametrical expression patterns in prostatospheroids derived from different cancer cell lines. For example, HNF4α showed significant upregulation in both LNCaP- and VCaP-prostatospheroids but downregulation in DU145-prostatospheroids; TRα and TRβ showed significant upregulation in DU145-prostatospheroids but no change in LNCaP- and VCaP-prostatospheroids, suggesting that these NRs might perform cell functions on spheroid formation in a cell-dependent manner. We also observed that only few NRs displayed downregulation in prostatospheroids (Supplementary Fig. 2). However, no common expression patterns were observed among these downregulated NRs in prostatospheroids (such as RARβ and ERα in LNCaP-prostatospheroids, CARα and DAX-1 in VCaP-prostatospheroids, PPARδ and HNF4α in DU145-prostatospheroids), suggesting that these downregulated NRs in prostatospheroids might be involved in functions other than spheroid formation or they play other roles in the differentiated anchorage-dependent prostate cancer cells.

**Castration-resistant prostate cancer xenografts contain increased population of CD44+/CD133+ cell population**

Based on the post-castration-relapse growth of AR-positive VCaP cells toward androgen withdrawal, we established a xenograft model of castration-resistant prostate cancer VCaP-CRPC (Fig. 3A). It is also known that besides AR, dysregulation of signaling pathways mediated by other hormone NRs, such as GR and progesterone receptor (PR), is also implicated to be involved in the castration-resistant growth of prostate cancer (Latil et al. 2001, Montgomery et al. 2014). To investigate the growth status of PCSCs in the VCaP-CRPC xenografts in response to castration, we used the qRT-PCR to survey the expression patterns of PCSC markers by qRT-PCR and also their relative cell population by FACS. Results of qRT-PCR showed that there were significant increases of expressions of multiple PCSC markers at 4-day post-castration and relapse growth at 2-month post-castration, as compared to that at pre-castration (Fig. 3A). Results of FACS also confirmed that there was significant increase in population of CD44+/CD133+ cells in VCaP-CRPC xenografts at 4-day post-castration (early response) and relapse growth at 2-month post-castration (late response) as compared to that at pre-castration (Fig. 3B). Immunofluorescence analysis also demonstrated that there was an increase in immunosignals of CD44 in VCaP-CRPC xenografts at 4-day post-castration and growth relapse at 2-month post-castration (Fig. 3C). Together, these results indicated that there was upregulation of PCSC-associated markers and also increase in population of PCSCs in the VCaP-CRPC xenografts during their refractory growth in response to castration.

**VCaP-CRPC xenografts display distinct expression profiles of NRs**

To identify the NR members differentially expressed in the castration-refractory growth of VCaP-CRPC xenografts, we used the qRT-PCR to profile the temporal expression pattern of all NR members in VCaP-CRPC xenografts at early (4-day) and late (2-month) post-castration by qRT-PCR. Results revealed that almost half of the members of NR superfamily showed altered expressions in post-castrated VCaP-CRPC xenografts as compared to pre-castrated xenografts, with most of the identified NR members showing significant upregulation (Fig. 4A). Further analysis showed that 14 NRs, including 4 endocrine NRs (VDR, TRβ, PR and MR), 4 adopted NRs (PPARγ, CARα, FXR and RXRγ) and 6 orphan NRs (Rev-erbβ, RORβ, TLX, COUP-TFI, NURR1 and LRH-1), were identified to express upregulation in VCaP-CRPC xenografts at both 4-day and 2-month post-castration (Fig. 4B). On the other hand, we detected only few NRs, which showed downregulation but with no consistent expression patterns, in the post-castrated VCaP-CRPC xenografts (Supplementary Fig. 3).

**Orphan NRs with common upregulation in prostatospheroids and castration-relapse VCaP-CRPC xenografts**

To identify the NR members that might play common roles in growth regulation of both prostatospheroids and VCaP-CRPC xenografts, we compared those NRs that show upregulation in both prostatospheroids and castration-relapse VCaP-CRPC xenografts. This pairwise comparison identified five orphan NRs (including RORα, TLX, COUP-TFI, NURR1 and LRH-1), which showed common upregulation in both prostate cancer cell lines-derived prostatospheroids and castration-relapse VCaP-CRPC xenografts (Fig. 5A). qRT-PCR and immunoblot analyses re-confirmed that these orphan NRs displayed significant upregulation in both prostatospheroids and castration-relapse VCaP-CRPC xenografts (Fig. 5B and C). Together, our results suggested that the identified orphan NRs might play common roles in the growth regulation of PCSCs and also contribute to the castration-relapse of prostate cancer.
Figure 3
Castration-relapse VCaP-CRPC xenografts contain more population of prostate cancer stem-like cells. (A) VCaP-CRPC xenografts were established based on the castration-relapse growth of VCaP xenografts in castrated host SCID mice (n=5). Left: Growth curve of VCaP tumor xenografts in host mice during 0–8 weeks after castration. Relapse of tumor growth occurred at 4-week post-castration. Right: qRT-PCR analysis. Results showed that the VCaP-CRPC xenografts expressed significantly higher mRNA levels of several PCSC-associated markers (CD44, CD24, OCT3/4, and CK5). (B) FACS analysis. Results showed that VCaP-CRPC tumor xenografts harvested at 4-day and 2-month post-castration contained increased population of CD44+CD133+ cells as compared to tumors harvested before castration. (C) CD44 immunofluorescence. Results showed that VCaP-CRPC tumor xenografts harvested at 4-day and 2-month post-castration expressed higher CD44 immunosignals at tumor cell membranes as compared to tumor cells harvested at pre-castration. Bars = 20 μm. *P < 0.05; **P < 0.01 vs pre-castration.
Z Wang, D Wu et al. Nuclear receptor profiling in prostate cancer

Figure 4

Castration-relapse VCaP-CRPC tumor xenografts display distinct expression profiles of NRs. (A and B) Histograms show the relative fold changes (RFC) of expression levels of NRs in VCaP-CRPC tumor xenografts harvested at 4-day and 2-month post-castration. Results revealed that over 20 NRs showing significant elevated expressions were identified in post-castrated VCaP-CRPC xenografts as compared to pre-castrated VCaP xenografts. (B) Left: data analysis showed that 14 NRs showing common upregulation were identified in VCaP-CRPC xenografts harvested at 4-day and 2-month post-castration. Right: a pie chart shows the NR numbers and a table shows the names of the identified upregulated NRs in the castration-relapse VCaP-CRPC tumor xenografts.

http://erc.endocrinology-journals.org
https://doi.org/10.1530/ERC-17-0280

© 2018 Society for Endocrinology
Published by Bioscientifica Ltd.
Printed in Great Britain

Downloaded from Bioscientifica.com at 10/22/2023 01:27:32PM via free access
Identified orphan NRs show upregulation in abiraterone-treated VCaP-CRPC xenografts and FACS-sorted CD133+-primary prostate cancer cells

To further provide an insight into the identified orphan NRs in CRPC progression and PCSCs, we next examined their mRNA expressions in VCaP-CRPC xenografts upon abiraterone treatment and FACS-sorted CD133+-primary prostate cancer cells isolated from clinical samples. Results showed that all the five orphan NRs exhibited increased expressions in the abiraterone-treated VCaP-CRPC xenografts and three of these NRs (TLX, NURR1 and LRH-1) displayed upregulation in FACS-sorted CD133+-primary prostate cancer cells (Fig. 6A and B). Moreover, using several publicly available oncogenic datasets of prostate cancer (Magee et al. 2001, Vanaja et al. 2003, Yu et al. 2004, Liu et al. 2006, Tomlins et al. 2007, Arredouani et al. 2009, Taylor et al. 2010, Grasso et al. 2012), we also validated that all the five orphan NRs showed increased expressions in clinical prostate cancer samples as compared to normal prostate gland (Fig. 6C). Our results further validated the upregulation patterns of the five orphan NRs in prostate cancer, and suggest that these NRs may play critical roles in prostate cancer and also PCSCs.

Overexpressions of five identified orphan NRs promote spheroid formation capacity of prostate cancer cells

Based on their common upregulation in both prostatospheroids and castration-relapse VCaP-CRPC xenograft tumors, we hypothesize that the identified orphan NRs might play positive roles in the advanced growth of prostate cancer, particularly the CRPC contributed by PCSCs. We then generated orphan NR infectants (including RORβ, TLX, COUP-TFII, NURR1 and LRH-1) in LNCaP- and DU145-derived prostatospheroids, and VCaP-CRPC xenograft model. Their expressions became reduced in prostatospheroid-derived re-adherent cells cultured under 2D culture condition. Similar to LNCaP/DU145-derived prostatospheroids, increased protein expressions of five orphan NRs were shown in 2-month post-castration VCaP-CRPC tumors. Representative figures shown above the blots represent the β-actin normalized levels relative to either adherent cells grown under 2D culture condition or pre-castration VCaP xenograft tumors.

Downloaded from Bioscientifica.com at 10/22/2023 01:27:32PM via free access
Figure 6
Upregulation of five identified orphan NRs shown in abiraterone-treated VCaP-CRPC xenografts, FACS-sorted CD133+ primary prostate cancer cells and clinical prostate cancer samples. (A) Abiraterone treatment of castration-relapse VCaP-CRPC xenograft model. qRT-PCR results showed that the abiraterone-treated VCaP-CRPC tumors expressed higher levels of the five identified orphan NRs (RORβ, TLX, COUP-TFII, NURR1 and LRH-1) as compared to vehicle-treated tumors. *P < 0.05; **P < 0.01 vs vehicle treatment. (B) FACS-sorted CD133+ primary prostate cancer cells. qRT-PCR results showed that the FACS-sorted CD133+ primary prostate cancer cells showed higher levels of TLX, NURR1 and LRH-1 as compared to CD133− cells. (C) Oncogenomic analysis of the five identified orphan NRs in prostate cancer clinical samples using the ONCOMINE datasets (http://www.oncomine.org). Results of expressions showed that higher log2 median-centered intensities of RORβ, TLX, COUP-TFII, NURR1 and LRH-1 were detected in clinical prostate cancer samples as compared to normal prostate gland tissues. Individual data points are presented as means (±s.e.m.) by boxplots of the log2 median-centered intensity where the greater intensity indicates greater gene expression. *P < 0.05; **P < 0.01 prostate carcinoma vs normal prostate.
In this study, we employed the real-time qRT-PCR to survey and compare the expression profiles of members of the entire NR superfamily in PCSC-enriched prostatospheroids grown under the non-adherent 3D-culture condition and the castration-relapse VCaP-CRPC tumor xenografts in order to identify the differentially expressed NRs in these prostate cancer models. Our findings revealed that both the 3D-cultured prostatospheroids and post-castrated VCaP-CRPC xenografts exhibited distinct expression profiles of NRs and also identified five orphan NRs that showed common upregulation pattern in both prostatospheroids and VCaP-CRPC tumor xenografts. Importantly, ectopic overexpression of these orphan NRs could increase expressions of some PCSC-associated markers and enhance the sphere formation capacity (stemness) in prostate cancer cells. The results suggested that the identified orphan NRs might perform certain roles in the regulation of PCSCs and also serve as potential biomarkers or therapeutic targets for CRPC.

Here, we identified a total of 21 NRs, showing common upregulation in PCSC-enriched prostatospheroids derived from three prostate cancer cell lines regardless of their AR expression status, many of which belong to the orphan NRs and have not been known or functionally characterized.
previously in prostate cancer or PCSCs. Their common expression patterns also suggest that these NRs may play positive roles in the growth and maintenance of PCSCs, as both prostaticspheroids and castration-relapse VCaP-CRPC xenografts contain increased population of PCSCs. Using a similar methodology, Xie et al. (2009) previously reported the expression profile of NR superfamily in both human and mouse embryonic stem cell lines. Comparing their dataset and ours, it is noted that 10 NRs (including GR, MR, RXRa, Rev-erba, RORα, TR4, COUP-TFI, COUP-TFII, NURR1 and LRH-1) show common expressions in both human embryonic stem cells and PCSCs. Indeed, a few of these orphan NRs have been described to be associated with PCSCs or androgen-independent prostate cancer cells. TR4 (NR2C2) is shown to be highly expressed in the CD133+-stem-like cell population derived from the androgen-insensitive and bone-metastatic prostate cancer cell line C4-2 and functionally associated with the chemoresistance of prostate cancer cells via the Oct4-IL-1 receptor signaling axis (Yang et al. 2013). COUP-TFI (NR2F1) is also demonstrated to be upregulated in circulating or disseminated tumor cells from prostate cancer patients carrying dormant disease and COUP-TFI-mediated signaling is characterized to be responsible for the control of quiescence or dormancy of prostate cancer cells in bone marrow via its regulation of targets SOX9 and RARβ, and global chromatin repression (Sosa et al. 2015). Similarly, we also identified 14 NRs, all of which have not been demonstrated previously to be expressed or associated with CRPC, showing upregulation in both short- and long-term post-castrated VCaP-CRPC xenografts. We have previously shown that PR (NR3C3) transcripts are detected in a few AR-positive prostate cancer cell lines (LNCaP, C4-2B) but not in immortalized prostatic epithelial cell lines (Cheung et al. 2005).

Here, we demonstrated that both 3D-cultured prostaticspheroids derived from either AR-positive or -negative prostate cancer cell lines and post-castrated VCaP-CRPC xenografts contained increased population of PCSCs. These results agree with the current notion that PCSCs play important roles not only in the tumor initiation but also the advanced growth of metastatic CRPC (Kerr & Hussain 2014). The PCSC-conferring castration or therapy resistance involves multiple pathways, including dysregulation of AR and androgen metabolism, aberrant or activated signaling pathways regulated by growth factor receptor tyrosine kinases and cytokines (PI3K-AKT, RAS-MAPK, STAT3), PTEN, Wnt, Notch and hedgehog (Ni et al. 2014, Rybak et al. 2015). Pairwise analysis identified five orphan NRs, namely RORβ, TLX, COUP-TFI, NURR1 and LRH-1, which showed common upregulation in both prostaticspheroids and post-castrated VCaP-CRPC xenografts. We also examined the expression patterns of the five orphan NRs in a CRPC-derived AR-positive cell line 22Rv1 and charcoal-stripped serum (CSS)-treated VCaP cells. Our results validated that all five orphan NRs showed increased expressions in 22Rv1-derived prostaticspheroids (Supplementary Fig. 4A, B and C) and CSS-treated VCaP cells (Supplementary Fig. 4D). Moreover, we also showed that all five orphan NRs exhibited increased expressions in the castration-refractory VCaP-CRPC xenograft model upon abiraterone treatment at the tumor relapse stage, suggesting that these orphan NRs may play roles in the abiraterone resistance in CRPC. Some of these identified orphan NRs (including TLX, LRH-1 and NURR1) also displayed upregulation in FACS-sorted CD133+-primary cultured prostate cancer cells isolated from clinical prostate cancer specimens. However, the specific roles or signaling pathways mediated by these orphan NRs in PCSCs or CRPC are yet to be defined and need further exploration. Recently, we have demonstrated that TLX (NR2E1), which exhibits an upregulated expression in prostate cancer tissues with high Gleason score, can function as a potent suppressor of oncogene-induced senescence in prostate cancer cells via its transcriptional co-regulation of two senescence-associated genes CDKN1A (p21) and SIRT1 (Wu et al. 2015). COUP-TFI (NR2F2), of which increased expression is positively correlated with the aggressiveness and recurrence of prostate cancer, can repress the AR transactivation in LNCaP prostate cancer cells and function to promote the Pten-null-mediated prostate tumorigenesis via its inhibition of TGF-β signaling as demonstrated in transgenic mouse studies (Song et al. 2012, Qin et al. 2013). Transient knockdown of NURR1 (NR4A2), which also displays increased expression in high Gleason score prostate cancer, can suppress the in vitro cell proliferation and migration of PC-3 prostate cancer cells (Wang et al. 2013).

In summary, our findings not only reveal the expression patterns of the entire NR superfamily in 3D prostaticspheroids and castration-resistant VCaP-CRPC xenograft model but also provide an insight into that some of the identified orphan NRs with common upregulations in these models could be useful as markers or potential therapeutic targets common for both the PCSCs and the therapy-resistant CRPC.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-17-0280.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by grants from the Hong Kong Research Grants Council (General Research Fund GRF, project numbers 14100914 and 14107116), Food and Health Bureau (Health and Medical Research Fund HMRF, grant number 02130066), CUHK (Direct Grant for Research, 2012.1.055) and National Natural Science Foundation of China (81502570).

Author contribution statement
Z W performed the experiments and drafted the manuscript. D W performed the 3D cultures, flow cytometric analysis and immunofluorescence. Y W performed the animal experiments. C F N and J Y C T provided clinical samples and interpreted results. S Y, Y W and F L C conceived the study and its design, obtained fundings for the study, drafted and revised the manuscript. All authors read and approved the final manuscript.

References
Kach J, Conzen SD & Szmulowitz RZ. 2015 Targeting the glucocorticoid receptor in breast and prostate cancers. Science Translational Medicine 7 305ps319. (https://doi.org/10.1126/scitranslmed.aac7531)


Mu X & Chang C 2003 TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3. Prostate 57 129–133. (https://doi.org/10.1002/pros.10282)


Mu X & Chang C 2003 TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3. Prostate 57 129–133. (https://doi.org/10.1002/pros.10282)


Received in final form 12 October 2017
Accepted 17 October 2017
Accepted Preprint published online 17 October 2017